Kane Biotech (TSE:KNE) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Kane Biotech has gained attention with a new publication in Pathogens journal and multiple conference presentations, highlighting the potential of their enzyme DispersinB® as a broad-spectrum antibiofilm agent. The company’s ongoing research efforts are showcased through presentations on the antibiofilm properties of revyve™ Antimicrobial Wound Gel Spray, signalling a commitment to advancing biofilm science and developing effective treatments for chronic wound infections.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.
